This is a Phase I study to evaluate the safety and efficacy of the \[68Ga\]Ga DOTA-5G and \[177Lu\]Lu DOTA-ABM-5G theranostics pair in patients with metastatic cancer.
Metastatic Cancer
This is a Phase I study to evaluate the safety and efficacy of the \[68Ga\]Ga DOTA-5G and \[177Lu\]Lu DOTA-ABM-5G theranostics pair in patients with metastatic cancer.
Molecularly Targeted Theranostic Approach for the Detection and Treatment of Metastatic Carcinomas
-
The University of California Davis Comprehensive Cancer Center, Sacramento, California, United States, 95817
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
University of California, Davis,
Julie L Sutcliffe, PRINCIPAL_INVESTIGATOR, University of California, Davis
2028-03-31